CPC A61K 31/122 (2013.01) [A61K 31/706 (2013.01); A61P 31/14 (2018.01)] | 18 Claims |
1. A method of treating a SARS CoV-2 infection in a human subject, comprising administering a combination of (i) hypericin or a pharmaceutically acceptable salt thereof and (ii) remdesivir or a pharmaceutically acceptable salt thereof to the human subject,
wherein the molar amount of the hypericin or a pharmaceutically acceptable salt thereof in the combination is greater than the molar amount of remdesivir or a pharmaceutically acceptable salt thereof,
thereby treating the SARS CoV-2 infection in the human subject.
|